Financial Performance - The company's operating revenue for the reporting period was CNY 1,580,502,489.40, representing an increase of 28.95% compared to CNY 1,225,632,600.83 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 33.25% to CNY 608,241,663.21 from CNY 911,231,777.09 in the previous year[18]. - Basic earnings per share decreased by 33.33% to CNY 0.52 from CNY 0.78 in the previous year[18]. - The company reported a total of CNY 47,803,182.98 in government subsidies recognized during the reporting period[22]. - The weighted average return on net assets decreased to 2.95% from 4.78% in the previous year, a decline of 1.83%[18]. - The company reported a total of CNY 22.76 million in new non-equity investments during the reporting period[62]. - The total operating revenue for the first half of 2018 was CNY 1,580,502,489.40, an increase of 29.0% compared to CNY 1,225,632,600.83 in the same period last year[167]. - The total operating costs amounted to CNY 1,399,527,071.76, up 32.9% from CNY 1,052,393,998.69 year-on-year[167]. - The net profit attributable to the parent company was CNY 608,241,663.21, a decrease of 33.2% from CNY 911,231,777.09 in the previous year[167]. - The total comprehensive income for the current period is 0.00, consistent with the previous period[170]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 24,484,060,158.46, an increase of 12.15% from CNY 21,831,626,601.10 at the end of the previous year[18]. - The company’s total investment for the period was CNY 1,552,650,362.49, a significant increase of 2,146.84% compared to the previous year[56]. - The company’s total liabilities rose to CNY 2,377,785,385.94, compared to CNY 401,897,825.27, indicating a significant increase[165]. - The company’s equity attributable to shareholders reached CNY 19,778,997,315.85, an increase from CNY 18,969,146,843.52[165]. - The total liabilities and equity amounted to CNY 22,156,782,701.79, up from CNY 19,371,044,668.79, reflecting a growth of 14.5%[165]. - The company’s long-term equity investments decreased by 4.60% in proportion to total assets, now accounting for 61.25%[52]. - The company’s inventory increased to CNY 560,923,408.62, reflecting a slight decrease in proportion to total assets by 0.23%[52]. Cash Flow - The net cash flow from operating activities increased significantly by 156.53% to CNY 188,370,631.11, compared to CNY 73,429,196.85 in the same period last year[18]. - The company’s cash and cash equivalents increased to CNY 1,427,518,742.77, up from CNY 1,156,199,229.89, reflecting a 0.32% increase in total asset proportion[52]. - The net cash flow from financing activities is 2,144,670,628.64, a turnaround from -331,135,893.12 in the previous period, indicating a positive shift[174]. - The net cash flow from investing activities is -2,164,201,031.38, contrasting with a positive cash flow of 21,725,058.08 in the previous period[175]. Investments - The company has invested a total of ¥40,000,000 in Yanbian Pharmaceutical, ¥20,000,000 in Yanji Pharmaceutical, ¥30,600,000 in Taonan Pharmaceutical, and ¥9,000,000 in Shihang Pharmaceutical to enhance its pharmaceutical technology and scale[37]. - The company completed a significant equity investment in Jilin Aodong Yanyuan Pharmaceutical Co., acquiring a 27.62% stake for CNY 400 million[58]. - The total investment amount for equity investments during the reporting period reached CNY 1.36 billion, with a cumulative profit of CNY 31.44 million[62]. - The company has ongoing major non-equity investments, including the Yanji Pharmaceutical large-volume injection project with an investment of CNY 273.82 million, achieving 99% completion[62]. - The company is actively pursuing market expansion and technological upgrades through its investment strategies[58]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company has committed to not selling or transferring its non-circulating shares for 36 months after obtaining listing circulation rights, with a maximum annual reduction of 2% of the total share capital at a price not lower than 7.5 yuan[77]. - The employee stock ownership plan holds 25,752,666 shares, accounting for 2.21% of the company's total share capital after the profit distribution plan was implemented[85]. - The company has not undergone any bankruptcy reorganization during the reporting period[80]. - The company has fulfilled its commitments regarding the share reform and has no overdue commitments as of the reporting period[78]. Market and Operational Strategy - The company plans to continue its "industry + finance" dual-driven growth model to enhance its market competitiveness[35]. - The company is focusing on product structure optimization and external development to enhance competitiveness and market share amid increasing market competition[71]. - The company plans to explore new operational models, including regional direct sales and product exports, to enhance its marketing strategy[41]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[180]. Environmental and Social Responsibility - The company has implemented a medicinal black bean planting project for poverty alleviation, which was successfully launched in April 2018[106]. - The company has established online monitoring equipment for pollutant emissions to ensure compliance with environmental protection requirements[104]. - The company has completed the construction and operation of pollution prevention facilities, with all major pollutants meeting environmental standards[102]. - The company has allocated CNY 12.97 million for targeted poverty alleviation work[110]. Compliance and Governance - The company did not report any significant changes in its accounting policies or financial reporting standards during the period[19]. - The half-year financial report has not been audited[79]. - The company has a good integrity status with no significant debts or court judgments pending[82]. - The company has not reported any non-operating related party debts or other significant contracts during the reporting period[95][96][100].

Financial Performance - The company's operating revenue for Q1 2018 was CNY 707,844,757.10, representing a 41.23% increase compared to CNY 501,196,830.07 in the same period last year[8] - Net profit attributable to shareholders decreased by 22.38% to CNY 324,731,039.98 from CNY 418,375,965.01 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 311,824,397.38, down 20.36% from CNY 391,551,827.56 in the previous year[8] - Basic and diluted earnings per share were both CNY 0.28, down 22.22% from CNY 0.36 in the same period last year[8] - The weighted average return on equity decreased to 1.59% from 2.21% year-on-year, a decline of 0.62%[8] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 139.59% to CNY 27,754,749.10, compared to CNY 11,584,483.10 in the same period last year[8] - Total assets at the end of the reporting period reached CNY 24,460,919,999.30, an increase of 11.93% from CNY 21,854,589,523.85 at the end of the previous year[8] - The net assets attributable to shareholders increased by 3.85% to CNY 21,080,701,054.18 from CNY 20,299,720,068.13 at the end of the previous year[8] - The company's cash and cash equivalents increased by 203.09% to ¥3,609,276,535.72 due to funds received from the public offering of convertible bonds[18] Expenses and Losses - The company reported a significant increase in sales expenses, which rose by 59.52% to ¥357,556,660.10, reflecting investments in new market development[18] - The financial expenses surged by 226.17% to ¥711,701.32, primarily due to interest accrued on convertible bonds[18] - The company experienced a 136.26% increase in asset impairment losses, totaling ¥10,209,537.82, due to higher bad debt provisions[18] Non-Operating Income and Other Income - The company reported non-operating income of CNY 12,906,642.60, which includes various non-recurring gains and losses[11] - Other income increased by 227.72% to ¥29,917,530.57, mainly from increased government subsidies[18] Investments - The total initial investment in securities amounted to ¥262,707,201.12, with a total loss of ¥23,846,591.34 during the reporting period[22] - The company held 10,210,800 shares of Haitong Securities, representing 0.09% of total shares, with a book value of ¥84,922,968.33 and a loss of ¥11,867,445.12[22] - The investment in Nanjing Pharmaceutical increased from 6,615,220 shares (0.74%) to 9,324,120 shares (0.90%), with a book value of ¥52,774,519.20 and a loss of ¥3,237,557.91[22] - The company reported a total of 64,741,470.94 shares held at the end of the period, with a total book value of ¥232,391,274.46[22] Market Strategy and Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20] Compliance and Governance - There were no violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[26][27] - The company did not engage in any derivative investments during the reporting period[24] Accounting Changes - The company’s investment in financial instruments was affected by a change in accounting policy, resulting in a negative impact of ¥133,004,104.71 on the equity attributable to shareholders[28] - The company holds a 17.26% stake in GF Securities, making it the largest shareholder, with a corresponding impact of -¥22,962,922.75 on the consolidated financial statements[29]

Financial Performance - The company's operating revenue for 2017 was CNY 2,976,771,644.51, representing an increase of 8.77% compared to CNY 2,736,697,077.39 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 1,863,471,361.46, reflecting an increase of 11.82% from CNY 1,666,491,361.24 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,708,064,399.15, up by 9.66% from CNY 1,557,610,982.16 in 2016[18]. - The basic earnings per share for 2017 was CNY 1.60, a 10.34% increase from CNY 1.45 in 2016[18]. - The total assets at the end of 2017 amounted to CNY 21,854,589,523.85, which is a 7.44% increase from CNY 20,340,503,252.70 at the end of 2016[18]. - The net assets attributable to shareholders at the end of 2017 were CNY 20,299,720,068.13, an increase of 8.91% from CNY 18,639,145,493.59 in 2016[18]. - The net cash flow from operating activities for 2017 was CNY 256,485,969.89, a decrease of 23.16% compared to CNY 333,812,958.37 in 2016[18]. - The weighted average return on net assets for 2017 was 9.59%, slightly up from 9.43% in 2016[18]. Revenue and Growth - In Q1 2017, the company reported operating revenue of ¥501.20 million, which increased to ¥989.54 million by Q4 2017, reflecting a growth of 97.0% over the year[22]. - The company achieved operating revenue of CNY 2,976.77 million, an increase of CNY 240.07 million, or 8.77% compared to the same period last year[34]. - The pharmaceutical segment contributed ¥2,888,055,937.04, accounting for 97.02% of total revenue, with a year-on-year growth of 8.45%[44]. - The company reported a total of 3,351 employees by the end of 2017, with 1,718 holding a college degree or higher[40]. Investments and Assets - The company achieved a 11.61% increase in long-term equity investments due to additional shares acquired in Guangfa Securities and its profitability[27]. - The company’s overseas investment in Hong Kong amounted to ¥507.07 million, contributing to its overall asset growth[29]. - The company holds 1,252,297,867 shares of Guangfa Securities, accounting for 16.93% of its total share capital[36]. - The total investment amount for the reporting period was CNY 954,478,031.40, a decrease of 32.80% from the previous year[70]. - The total investment income amounted to CNY 1,481,178,161.93, accounting for 76.62% of total profit, mainly from investments in Guangfa Securities[63]. Research and Development - The company has maintained a strong focus on R&D, enhancing its product competitiveness and operational efficiency, which is crucial in the pharmaceutical industry[25]. - Research and development investment amounted to 94,130,909.05 CNY, which is 3.16% of total operating revenue, showing a slight decrease from 3.31% in 2016[57]. - Jilin Aodong is investing 100 million CNY in R&D for new drug development, focusing on innovative therapies[180]. Dividend Policy - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) to all shareholders[6]. - In 2017, the total cash dividend amounted to 348,830,988.60 yuan, representing 18.72% of the net profit attributable to ordinary shareholders, which was 1,863,471,361.46 yuan[102]. - The company has maintained a consistent cash dividend policy over the past three years, with clear standards and procedures in place[101]. Corporate Governance - The company appointed Zhongzhun Accounting Firm as its auditor for the 2017 financial report, with an audit fee of 700,000 CNY[111]. - The independent directors have fulfilled their responsibilities in the decision-making process regarding the cash dividend policy[100]. - The governance structure complies with the regulatory standards set by the China Securities Regulatory Commission[200]. Social Responsibility - The company emphasizes social responsibility and aims for harmonious development with the environment and society[139]. - The company allocated RMB 3 million for poverty alleviation efforts, including a donation of RMB 2 million to the "Poverty Alleviation" project and the establishment of a goat breeding farm[143][145]. - A total of 1,261 registered impoverished individuals were helped to escape poverty through various initiatives[143]. Employee Relations - The company has implemented a transparent and fair employee selection mechanism, enhancing team cohesion and competitiveness[40]. - The remuneration for the chairman, Li Xiulin, was 3.89 million yuan, while the general manager, Guo Shuqin, received 2.01 million yuan[190]. - The company follows a performance-based salary system, with remuneration determined by job position and company performance[189]. Market Strategy - The company is adapting its marketing strategies to align with new healthcare policies, aiming to optimize its sales structure and enhance product positioning[90]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2020[180]. - The company is implementing new digital marketing strategies, projected to increase online sales by 30% in 2018[180].

Financial Performance - Operating revenue for the reporting period was ¥761.60 million, representing a year-on-year growth of 19.37%[8] - Net profit attributable to shareholders was ¥458.35 million, up 3.37% from the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥424.22 million, a slight increase of 0.45%[8] - Basic earnings per share for the reporting period were ¥0.3942, reflecting a growth of 2.36%[8] - The weighted average return on net assets was 2.37%, a decrease of 0.16% compared to the previous year[8] - The net cash flow from operating activities for the year-to-date was ¥144.16 million, down 28.17%[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 86,993[13] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.66% of the shares, amounting to 309,940,049 shares[13] Non-Recurring Items - Non-recurring gains and losses totaled ¥92.29 million for the year-to-date, after accounting for tax and minority interests[10] Asset and Liability Changes - Total assets at the end of the reporting period reached ¥21.64 billion, an increase of 6.40% compared to the end of the previous year[8] - The balance of financial assets measured at fair value decreased by 44.31% compared to the beginning of the year, mainly due to a reduction in short-term stock investments[17] - Accounts receivable increased by 65.07% compared to the beginning of the year, primarily due to an increase in receivables from pharmaceutical sales[17] - Prepayments increased by 216.27% compared to the beginning of the year, mainly due to an increase in advance payments for raw materials[17] - The balance of short-term borrowings decreased by 92.58% compared to the beginning of the year, mainly due to repayments by a subsidiary[17] - The company’s total liabilities decreased significantly, with employee compensation liabilities down by 72.62% compared to the beginning of the year[17] Investment Activities - The net cash flow from investing activities decreased by 55.96% compared to the same period last year, primarily due to an increase in cash paid for investments[19] - The total investment cost for securities held by the company amounts to ¥228,924,667.77, with a fair value change loss of ¥2,137,419.37 during the reporting period[26] - The company reported a fair value of ¥185,877,205.71 at the beginning of the period, and the ending book value is ¥241,908,513.74[26] - The company holds a significant investment in Haitong Securities (06837.HK) with a fair value of ¥81,393,941.00, reflecting a loss of ¥5,502,427.05 during the period[26] - The investment in China Ping An (601318) shows a fair value of ¥46,036,000.00, with a profit of ¥36,401,676.47 reported[26] - The total fair value of available-for-sale financial assets is reported at ¥865,576,120.48, with a total initial investment cost of ¥735,196,658.00[27] Social Responsibility and Community Engagement - The company has invested ¥200,000 in poverty alleviation projects, focusing on agricultural and forestry industry development[34] - The company plans to continue its poverty alleviation efforts by promoting related farming and breeding industries, aiming for precise poverty alleviation[35] - The company actively engages in social responsibility initiatives, particularly in poverty alleviation, creating job opportunities in impoverished areas[33] Other Financial Information - Other comprehensive income increased by 54.32% compared to the beginning of the year, attributed to gains from an associated company[18] - The company’s tax expenses increased by 52.25% compared to the same period last year, due to adjustments in tax accounting[18] - The company has no derivative investments during the reporting period[29] - There are no violations regarding external guarantees or non-operational fund occupation by major shareholders[31][32]

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 1,225,632,600.83, representing a 0.72% increase compared to CNY 1,216,930,561.84 in the same period last year[19]. - Net profit attributable to shareholders was CNY 911,231,777.09, an increase of 8.70% from CNY 838,262,901.71 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 853,073,621.82, up 2.93% from CNY 828,781,689.14 in the previous year[19]. - Basic and diluted earnings per share increased by 8.33% to CNY 0.78, compared to CNY 0.72 in the previous year[19]. - The company's revenue for the period was CNY 1,225.63 million, reflecting a year-on-year increase of CNY 8.70 million or 0.72%[37]. - The company's total assets reached CNY 20,971.16 million, an increase of CNY 630.65 million or 3.10% compared to the beginning of the year[37]. - The weighted average return on equity was 4.78%, slightly down from 4.80% in the previous year[19]. - The company's total assets increased to CNY 18,654,707,667.47, compared to CNY 18,026,077,434.60 in the previous period[130]. - Earnings per share (EPS) for the period was CNY 0.78, an increase from CNY 0.72 in the same period last year[132]. - The company reported a significant increase in long-term equity investments, rising to CNY 13,809,790,881.87 from CNY 13,451,099,425.55, an increase of approximately 2.7%[124]. Cash Flow and Investments - The net cash flow from operating activities decreased by 41.81% to CNY 73,429,196.85, down from CNY 126,197,102.81 in the same period last year[19]. - Cash inflow from investment activities reached CNY 5,625,435,856.44, significantly up from CNY 2,750,526,988.80, marking a 104.3% increase[138]. - Cash outflow from financing activities was CNY 873,815,059.23, down from CNY 1,487,134,929.56, indicating a 41.2% reduction[139]. - The ending balance of cash and cash equivalents was CNY 1,156,199,229.89, up from CNY 640,124,939.86[139]. - The company invested ¥69,103,706.46 during the reporting period, a decrease of 33.05% compared to the previous year[53]. - The company has invested approximately ¥2.7 billion in 10 projects across various fields including biopharmaceuticals and medical devices[43]. Assets and Liabilities - Total liabilities decreased to CNY 1,355,317,897.23 from CNY 1,466,468,740.58, a reduction of approximately 7.6%[125]. - Shareholders' equity increased to CNY 19,615,840,333.38 from CNY 18,874,034,512.12, reflecting a growth of about 3.9%[125]. - The asset-liability ratio stands at 6.46%, indicating a strong financial position[37]. - The total financial assets at the end of the period were ¥1,091,408,185.42, with significant transactions including purchases of ¥5,516,736,260.42 and sales of ¥5,553,509,210.38[50]. Dividends and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company distributed a cash dividend of 3.00 CNY per 10 shares (including tax) and issued 3 bonus shares per 10 shares to all shareholders based on a total of 894,438,433 shares[79]. - The total number of ordinary shareholders at the end of the reporting period was 88,798, with the largest shareholder holding 26.66% of the shares[108]. - The company’s largest shareholder, Dunhua Jincheng Industrial Co., Ltd., increased its holdings by 71,524,627 shares during the reporting period[108]. Corporate Governance and Management - The company held a board meeting on June 23, 2017, to approve the nomination of candidates for the ninth board of directors and the supervisory board[97]. - The company’s board of directors and supervisory board were re-elected during the first extraordinary general meeting held on July 17, 2017[117]. - The company appointed Guo Shuqin as the general manager and Zhang Shuyuan as the CFO during the first board meeting of the ninth board of directors[99]. - The company approved an employee stock ownership plan in July 2016[78]. Market and Operational Strategy - The company is actively exploring new product development and market expansion in health food and agriculture sectors[27]. - The company is focused on the production of various pharmaceutical products, including traditional Chinese medicine and health food, which aligns with market demand[63]. - The company emphasizes a market-oriented approach, focusing on major and multiple product groups for stable development[67]. - The company is engaged in various sectors, including pharmaceutical manufacturing and research, which supports its growth strategy[154]. Social Responsibility and Community Engagement - The company donated 2 million CNY to the charity fund of Taonan City for poverty alleviation projects during the reporting period[93]. - The company plans to continue its poverty alleviation efforts through industrial development, financial assistance, and participation in social charity activities[96]. Compliance and Reporting - The half-year financial report has not been audited[74]. - The financial report was approved by the board on August 25, 2017, and disclosed on August 26, 2017, ensuring transparency in financial reporting[154]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial position and operating results[160].

Financial Performance - The company's operating revenue for Q1 2017 was ¥501,196,830.07, a decrease of 11.73% compared to ¥567,773,907.19 in the same period last year[8] - Net profit attributable to shareholders increased by 15.12% to ¥418,375,965.01 from ¥363,410,249.92 year-on-year[8] - Basic and diluted earnings per share rose by 14.63% to ¥0.47 from ¥0.41 in the same period last year[8] - Total assets at the end of the reporting period were ¥20,989,757,399.24, reflecting a 3.19% increase from ¥20,340,503,252.70 at the end of the previous year[8] - Net assets attributable to shareholders increased by 3.17% to ¥19,229,237,005.98 from ¥18,639,145,493.59 year-on-year[8] Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥11,584,483.10, a 176.62% increase from a negative cash flow of ¥15,118,732.74 in the previous year[8] - The net cash flow from operating activities increased by 176.62% compared to the same period last year, primarily due to increased cash receipts from drug sales[16] - The net cash flow from investing activities increased by 79.83% compared to the same period last year, mainly due to an increase in cash received from investment recoveries[17] - The net cash flow from financing activities increased by 119.86% compared to the same period last year, primarily due to a decrease in cash paid for repaying short-term loans[17] Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥26,824,137.45 for the period[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,388[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.66% of the shares, amounting to 238,415,422 shares[11] Expenses and Income - Tax expenses increased by 33.63% compared to the same period last year, mainly due to the adjustment of property tax and land use tax to the "taxes and surcharges" account[15] - Financial expenses decreased by 111.68% compared to the same period last year, mainly due to a reduction in bank loan interest payments[15] - Asset impairment losses decreased by 56.81% compared to the same period last year, mainly due to a decrease in bad debt losses recognized[15] - Operating income from non-operating activities increased by 64.69% compared to the same period last year, mainly due to an increase in government subsidies recognized in the current period[15] Investments - The total investment in securities at the end of the reporting period amounted to CNY 532,072,403.04, with a report period profit of CNY 15,342,290.25[20] - The company held 64,308,554 shares at the end of the reporting period, an increase from 55,078,845 shares at the beginning[20] - The investment in China Ping An increased from 3,432,200 shares (0.02%) to 4,772,000 shares (0.03%) during the reporting period[20] - The investment in CITIC Securities rose from 4,950,000 shares (0.04%) to 11,183,500 shares (0.09%)[20] - The investment in China Reinsurance remained stable at 7,123,000 shares (0.02%) throughout the reporting period[20] - The total value of other securities investments at the end of the reporting period was CNY 22,921,529.74, with a profit of CNY 1,005,493.96[20] Other Information - The company did not engage in any repurchase agreements during the reporting period[12] - The company did not engage in any derivative investments during the reporting period[21] - There were no violations regarding external guarantees during the reporting period[23] - The company reported no non-operating fund occupation by controlling shareholders or related parties[24] - The company conducted a communication session regarding its production and operation status during the reporting period[22] - The ending balance of prepaid expenses increased by 112.81% compared to the beginning of the year, mainly due to the increase in prepayments for raw material purchases[15] - The fair value change income increased by 140.50% compared to the same period last year, mainly due to the impact of fair value changes in trading financial assets such as stocks and funds[15] - Other comprehensive income attributable to owners of the parent company increased by 156.06% compared to the same period last year, mainly due to the increase in other comprehensive income of the associated company Guangfa Securities[15]

Financial Performance - The company's operating revenue for 2016 was CNY 2,736,697,077.39, representing a 17.22% increase compared to CNY 2,334,760,837.13 in 2015[17]. - The net profit attributable to shareholders decreased by 35.75% to CNY 1,666,491,361.24 from CNY 2,593,589,316.67 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 1,557,610,982.16, down 37.22% from CNY 2,480,906,545.47 in 2015[17]. - The net cash flow from operating activities was CNY 333,812,958.37, a decrease of 13.97% compared to CNY 388,032,364.72 in 2015[17]. - Basic earnings per share fell by 34.83% to CNY 1.89 from CNY 2.90 in the previous year[17]. - The company reported a weighted average return on equity of 9.43%, down from 17.33% in 2015, reflecting a decrease of 7.90%[17]. - Quarterly operating revenue for Q4 2016 was CNY 881,754,458.59, contributing to the overall annual revenue growth[20]. - The net profit attributable to shareholders was CNY 363,410,249.92, a decrease from CNY 474,852,651.79 in 2015, representing a decline of approximately 23.5%[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 365,430,866.85, down from CNY 463,350,822.29 in 2015, indicating a decrease of about 21.1%[21]. - The net cash flow from operating activities was negative CNY 15,118,732.74, contrasting with a positive CNY 141,315,835.55 in 2015[21]. Assets and Investments - Total assets at the end of 2016 were CNY 20,340,503,252.70, an increase of 2.55% from CNY 19,834,016,266.66 at the end of 2015[17]. - The net assets attributable to shareholders increased by 7.25% to CNY 18,639,145,493.59 from CNY 17,378,771,619.39 in 2015[17]. - Long-term equity investments increased by 2.15% compared to the beginning of the year, primarily due to additional shares acquired in Guangfa Securities[27]. - Fixed assets grew by 18.44% year-on-year, mainly due to the completion of construction projects in subsidiaries[27]. - The company’s total revenue from the food segment was ¥58,006,717.69, reflecting an 8.54% increase from ¥53,442,359.35 in 2015[44]. - The company reported a total investment of ¥1,420,415,336.37 during the reporting period, a decrease of 20.35% compared to ¥1,783,395,983.21 in the same period last year[65]. - The company’s total current assets as of December 31, 2016, amounted to CNY 3,239,531,829.74, an increase from CNY 3,156,822,361.18 at the beginning of the year, reflecting a growth of approximately 2.6%[200]. - The company's total non-current assets reached CNY 13,451,099,425.55, up from CNY 13,167,483,356.03, indicating an increase of approximately 2.1%[200]. Dividends and Shareholder Information - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) and issue 3 bonus shares per 10 shares (including tax) based on a total of 894,438,433 shares[6]. - The cash dividend amount for 2016 was CNY 268,331,529.90, representing 16.10% of the net profit attributable to ordinary shareholders, which was CNY 1,666,491,361.24[100]. - In 2015, the cash dividend was CNY 262,388,607.00, accounting for 10.12% of the net profit of CNY 2,593,589,316.67[100]. - The total number of shareholders at the end of the reporting period was 94,273, an increase from 86,705 at the end of the previous month[145]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 170,687,108 shares, representing 26.66% of total shares[146]. - The company’s total share capital remains at 894,438,433 shares, with 92.21% being unrestricted shares[142]. Corporate Governance and Compliance - The company has a strong commitment to corporate governance and transparency in its operations[160]. - The company has maintained stable leadership with no changes in the board of directors or senior management during the reporting period[156]. - The company has established a scientific salary system based on job positions and company performance[166]. - The company emphasizes training to enhance core competitiveness and improve employee skills through various training methods[167]. - The company has implemented a strict insider information management system to prevent the leakage of non-public significant information[174]. - The audit report issued by the accounting firm confirmed a standard unqualified opinion on the financial statements for the year ended December 31, 2016[193]. - The company has established a comprehensive compensation management system and performance evaluation system for senior management[186]. Research and Development - The company is advancing the research and development of new products, including "Aodong Brand Zao Ren Yi Shen Oral Liquid" and "Injection of Hydrochloride Boanmycin" for additional indications[87]. - Research and development expenses amounted to CNY 90,556,593.18 in 2016, a decrease of 3.88% from CNY 94,209,378.30 in 2015, representing 3.31% of total revenue[55]. - The company emphasizes a comprehensive quality control system to ensure the highest standards in production, focusing on five key aspects: people, machines, materials, methods, and environment[87]. Social Responsibility and Community Engagement - The company allocated a total of RMB 300,000 for targeted poverty alleviation efforts in 2016[130]. - A total of 384 registered impoverished individuals were lifted out of poverty through the company's initiatives[131]. - The company invested RMB 11.39 million in agricultural development projects aimed at poverty alleviation, benefiting 93 individuals[131]. - The company provided RMB 8.17 million in financial support for 94 impoverished students[131]. - The company’s environmental protection expenditure amounted to RMB 4.0097 million in 2016[136]. - The company made social welfare donations totaling RMB 1.4893 million[136]. Market Strategy and Future Outlook - The company plans to enhance production automation and smart construction in its pharmaceutical subsidiaries to improve overall competitiveness[87]. - The company will continue to focus on internal growth while exploring acquisition opportunities to achieve external growth and enhance efficiency[90]. - The company has shifted focus away from the sanitary products sector, leading to a 100% decrease in sales and procurement in that category[47]. - The company aims to distribute cash dividends of 3.00 yuan per 10 shares, totaling approximately 268.33 million yuan, which represents 50% of the total profit distribution[98].

2016 年第三季度报告正文 1 吉林敖东药业集团股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 吉林敖东药业集团股份有限公司 2016 年第三季度报告正文 证券代码：000623 证券简称：吉林敖东 公告编号：2016-046 吉林敖东药业集团股份有限公司 所有董事均已出席了审议本次季报的董事会会议。 公司董事长李秀林先生、总经理朱雁先生、财务总监张淑媛女士及会计主 管人员李强先生声明：保证季度报告中财务报表的真实、准确、完整。 2 吉林敖东药业集团股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 19,328,496,425.71 | 19,834 ...

Financial Performance - The company's operating revenue for the reporting period was CNY 1,216,930,561.84, representing a 6.88% increase compared to CNY 1,138,644,975.94 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 49.50% to CNY 838,262,901.71 from CNY 1,659,945,613.45 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 828,781,689.14, down 48.81% from CNY 1,619,176,395.26 year-on-year[17]. - Basic earnings per share decreased by 49.46% to CNY 0.94 from CNY 1.86 in the previous year[17]. - The company reported a significant decrease in total profit to ¥874,109,091.64 from ¥1,693,285,757.60, a decline of 48.3%[116]. - The investment income decreased significantly to ¥652,097,536.56 from ¥1,476,223,796.70, a drop of 55.8%[116]. - The gross profit margin for the overall business was 70.63%, a decrease of 12.63% compared to the previous year[38]. Cash Flow and Assets - The net cash flow from operating activities increased by 28.67% to CNY 126,197,102.81, compared to CNY 98,076,678.98 in the same period last year[17]. - The company's cash and cash equivalents decreased to ¥640,124,939.86 from ¥1,849,884,928.42, representing a decline of approximately 65.4%[108]. - Total assets at the end of the reporting period were CNY 19,616,901,093.62, a decrease of 1.09% from CNY 19,834,016,266.66 at the end of the previous year[17]. - The total current assets amounted to ¥3,321,699,227.22, up from ¥3,156,822,361.18, indicating an increase of approximately 5.2%[108]. - The total cash outflow from investing activities was 3,209,055,537.00 CNY, compared to 4,098,865,739.88 CNY in the previous period, indicating a decrease of about 21.6%[123]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company distributed a cash dividend of RMB 3 per 10 shares to shareholders based on the total share capital of 894,438,433 shares as of the end of 2015[53]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 25.92% of the shares, amounting to 231,796,333 shares[92]. - The company has a total of 894,438,433 shares, with 90.22% being unrestricted shares[92]. Investments and Subsidiaries - The company holds a 16.70% stake in Guangfa Securities, with a book value of ¥12,366,595,558.72 and a reported gain of ¥672,760,008.95 during the reporting period[42]. - The subsidiary Jilin Aodong Yanyuan Pharmaceutical Co., Ltd. reported a net profit of RMB 33.47 million on revenue of RMB 392.39 million[52]. - The company established several investment funds in collaboration with Guangfa Securities to enhance resource and capital interaction[31]. Operational Changes and Management - The company is focusing on improving product quality management and has established a comprehensive supplier database to ensure quality control[26]. - The company has initiated secondary development projects for existing products, leveraging partnerships with academic institutions for quality standard enhancements[26]. - The company’s management structure promotes a decentralized governance model, enhancing operational efficiency and stability[40]. Compliance and Governance - The company has established a complete internal control system to ensure compliance and asset security[60]. - There were no significant litigation or arbitration matters during the reporting period[61]. - The company confirmed that there are no significant issues regarding its ability to continue as a going concern for the next 12 months[139]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements reflect true and complete financial conditions[141]. - The company uses Renminbi as its functional currency for domestic operations, while foreign subsidiaries use their respective local currencies[144]. - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, such as significant financial difficulties of the issuer or debtor[171].

Financial Performance - The company's operating revenue for Q1 2016 was ¥567,773,907.19, representing an increase of 8.17% compared to ¥524,888,874.41 in the same period last year[7]. - The net profit attributable to shareholders decreased by 38.07% to ¥363,410,249.92 from ¥586,843,767.58 year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 35.77% to ¥365,430,866.85 compared to ¥568,956,135.09 in the previous year[7]. - Basic and diluted earnings per share decreased by 37.88% to ¥0.41 from ¥0.66 year-on-year[7]. - The weighted average return on net assets dropped to 2.09%, down by 2.43% from 4.52% in the previous year[7]. - Net profit attributable to the parent company decreased by 38.07% year-on-year, mainly due to a decrease in net profit from Guangfa Securities[16]. - Investment income decreased by 43.83% year-on-year, primarily due to a decrease in net profit attributable to the parent company from Guangfa Securities[15]. - Other comprehensive income after tax decreased by 255.82% year-on-year, mainly due to a reduction in other comprehensive income from Guangfa Securities[16]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥15,118,732.74, a significant decline of 2,071.61% from -¥696,199.93 in the same period last year[7]. - Cash flow from operating activities decreased by 2,071.61% year-on-year, mainly due to a reduction in business receivables and increased cash payments for raw materials[16]. - Cash flow from investing activities decreased by 69.45% year-on-year, primarily due to increased investments in Guangfa Securities[16]. - Total assets at the end of the reporting period were ¥19,934,404,787.52, a slight increase of 0.51% from ¥19,834,016,266.66 at the end of the previous year[7]. - The net assets attributable to shareholders increased by 0.33% to ¥17,435,893,869.74 from ¥17,378,771,619.39 at the end of the previous year[7]. - Other non-current assets increased by 109.52% compared to the beginning of the year, mainly due to increased payments for projects and equipment[14]. - Deferred income tax liabilities decreased by 38.40% compared to the beginning of the year, mainly due to a reduction in deferred tax liabilities from available-for-sale financial assets[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 99,507[10]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 25.92% of the shares, amounting to 231,796,333 shares, with 186,120,000 shares pledged[10]. - The total number of shares held at the end of the period is 32,036,707.58, with a corresponding book value of ¥158,053,100.41[20]. Investments and Market Activity - The total investment in securities amounts to ¥156,252,858.61, with a total loss of ¥14,228,245.89 during the reporting period[20]. - The company holds 1,750,000 shares of China Ping An, with an initial investment of ¥67,203,420.36, resulting in a loss of ¥7,332,500.00[20]. - The investment in the fund "Guangfa Core Select" is valued at ¥8,929,592.43, with a loss of ¥1,549,955.16 during the reporting period[20]. - The company has no derivative investments during the reporting period[21]. Compliance and Communication - There were no violations regarding external guarantees during the reporting period[23]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[24]. - The company engaged in communication activities regarding its production and operation from January 1 to March 31, 2016[22]. - The company has not provided any forecasts for the first half of 2016[20].